Month: August 2023

Initiation cleared for 50 mg cohort in Phase 2 Friedreich’s ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 data Initiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 data Top-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial’s 50 mg cohort expected in 1H 2024 Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Cash, cash equivalents and marketable securities of $104.2 million as of June 30, 2023, provides projected cash runway into Q4 2024BALA CYNWYD, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported...

Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment in IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcell™ in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be held today, August 10, 2023, at 8:30 am EDT GAITHERSBURG, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended June 30, 2023, and provided a business update. “We are pleased to have commenced enrollment in our IMPACT Phase 2b biopsy-driven trial of pemvidutide in NASH,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We believe our compelling Phase 1b data in subjects with nonalcoholic...

Figure 1Quarterly Production and AISC ChartFigure 2Quarterly Total Ore Processed, Development Metres Advanced and Total Mined Material ChartVANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce financial results for the three months ended June 30, 2023. ProductionStrong quarterly production of 30,794 ounces gold equivalent (“AuEq”) (1) (2) or 27,405 oz gold, 1,526,547 lbs copper and 34,001 oz silver, representing an 18% increase from Q2 2022 and 43% increase from Q1 2023. Cash costs of US$597/oz gold (2) and all-in sustaining costs (“AISC”) of US$975/oz gold (2), notably better than the annual guidance of US$620-680/oz gold cash costs(2) and US$1,180 to US$1,300/oz gold AISC (2). Strong metallurgical recoveries of...

Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation; updated clinical data expected in the fourth quarter Raised up to $185 million, including $35 million upfront, from leading investors Successfully completed a non-human primate study for subcutaneous tegoprubart formulation IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its second quarter operating and financial results and reviewed recent business highlights. “We have now transplanted nine patients in our ongoing Phase 1b kidney transplantation trial and remain highly encouraged by the results to date,” said David-Alexandre C. Gros, M.D., Chief Executive Officer. “We believe that tegoprubart could represent a significant advancement in immunosuppressive...

Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023 as SG&A and R&D expenses decreased by $22M or 33% compared to first half 2022 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2023, and provided operational updates. “We are pleased with the progress we made in the second quarter of 2023 towards our strategic objectives,” stated CEO Ramy Mahmoud, MD, MPH. “That means we are outperforming our initial expectations...

Record quarterly revenue of $485.2 million, including comparable restaurant sales growth of 10.5% Top-line strength helped deliver another quarter of improved profitability SYRACUSE, N.Y., Aug. 10, 2023 (GLOBE NEWSWIRE) — Carrols Restaurant Group, Inc. (“Carrols” or the “Company”) (Nasdaq: TAST), the largest BURGER KING® franchisee in the United States, today reported its financial results for the second quarter ended July 2, 2023. Highlights for the Second Quarter of 2023 versus the Second Quarter of 2022 include:Total restaurant sales increased 9.8% to $485.2 million in the second quarter of 2023 compared to $441.9 million in the second quarter of 2022; Comparable restaurant sales for the Company’s Burger King® restaurants increased 10.4%; Comparable restaurant sales for the Company’s Popeyes® restaurants increased 11.6%; Adjusted...